1. Introduction {#sec1-jcm-09-02013}
===============

Childhood onset nephrotic syndrome (NS) generally responds well to conventional oral corticosteroid therapy, and steroid-sensitive NS has a benign long-term renal prognosis even though it shows frequent relapses. However, 10--20% of pediatric NS cases are steroid-resistant nephrotic syndrome (SRNS), which does not achieve remission by oral corticosteroid therapy. SRNS is one of the most common causes of end-stage renal disease (ESRD) in childhood, and the common pathological finding in SRNS is focal segmental glomerulosclerosis (FSGS) \[[@B1-jcm-09-02013]\].

Furthermore, SRNS is highly heterogeneous both phenotypically and genetically and can occur at any age, manifesting as isolated proteinuria or fully developed NS. In addition, various kinds of syndromic diseases may manifest SRNS as a renal phenotype along with characteristic extrarenal phenotypes. To date, at least 50 monogenic causes of SRNS or FSGS have been identified, and novel causative genes are constantly being discovered \[[@B2-jcm-09-02013]\].

Recent advances in next-generation sequencing (NGS) techniques make genetic diagnosis more feasible in SRNS patients. Recent large cohort studies \[[@B3-jcm-09-02013],[@B4-jcm-09-02013],[@B5-jcm-09-02013],[@B6-jcm-09-02013]\] revealed genetic mutations in approximately 30% of pediatric patients with SRNS/FSGS. Benefits of genetic diagnosis in patients with SRNS include providing definitive diagnosis and valuable information for decisions on treatment policy and prediction of prognosis.

Genetic testing modalities currently used for SRNS include Sanger sequencing, targeted exome sequencing (TES) with gene panels, whole exome sequencing (WES) and whole-genome sequencing (WGS) \[[@B7-jcm-09-02013],[@B8-jcm-09-02013],[@B9-jcm-09-02013],[@B10-jcm-09-02013],[@B11-jcm-09-02013]\]. Sanger sequencing can be effectively applied to test a single or few candidate genes using a gene-by-gene approach. Candidate genes can be easily identified clinically in patients with typical extrarenal phenotypes of syndromic diseases. In addition, one of the four candidate genes (*NPHS1, NPHS2, WT1*, and *LAMB2*) can be identified in more than 85% of patients with congenital onset \[[@B12-jcm-09-02013],[@B13-jcm-09-02013]\]. Sanger sequencing is still regarded as the gold standard, and variants detected by NGS should be confirmed by Sanger sequencing \[[@B14-jcm-09-02013]\]. In patients whose candidate genes are not identified clinically, gene-by-gene Sanger sequencing of more than 50 known candidate genes for SRNS is a time-consuming and costly test. Instead, TES with gene panels can provide a rapid and cost-effective test by sequencing a set of all known genes relevant to SRNS simultaneously. Notably, some patients with syndromic disorders manifest no or mild/atypical extrarenal phenotypes. In these cases, the suspected underlying genetic syndrome cannot be identified clinically, but TES is able to detect the disease-causing mutations \[[@B14-jcm-09-02013]\]. However, TES cannot detect mutations in novel or phenocopying genes unless these genes are included in the panels. Another disadvantage of TES is rapidly outdated gene panels due to the continuous discovery of novel disease-causing genes. Despite these drawbacks, TES with gene panels is currently considered the most cost-effective approach for indication-driven mutation analysis \[[@B10-jcm-09-02013],[@B14-jcm-09-02013]\].

Compared with TES gene panels, WES is an unbiased approach to genetic diagnosis by sequencing entire exons, i.e., all protein-coding regions of the genome. Therefore, WES can identify not only known gene mutations but also novel disease-causing genes. Current limitations of WES include issues with lower coverage of some exons, high costs and difficulty in handling enormous amounts of data \[[@B8-jcm-09-02013],[@B9-jcm-09-02013],[@B10-jcm-09-02013],[@B11-jcm-09-02013],[@B14-jcm-09-02013]\]. A more complete per-base coverage can be provided by WGS, but the cost and interpretation issues are larger than in WES \[[@B8-jcm-09-02013],[@B9-jcm-09-02013],[@B14-jcm-09-02013]\]. Currently, Sanger sequencing or TES is used as the first-line test for the genetic diagnosis of SRNS, and WES or WGS can be used when the first-line test shows negative results \[[@B8-jcm-09-02013],[@B9-jcm-09-02013],[@B10-jcm-09-02013],[@B11-jcm-09-02013],[@B14-jcm-09-02013]\]. In this study, 127 patients had disease-causing mutations, including 80 (63.0%) patients diagnosed by Sanger sequencing, 40 (31.5%) by TES, and 4 (3.1%) by WES.

Like most genetic disorders, hereditary SRNS shows ethnic and geographic differences. However, there have been no large-scale genetic studies for pediatric patients with SRNS/FSGS in Korea. In this study, phenotype-genotype correlations were studied in a cohort of Korean pediatric patients with SRNS/FSGS.

2. Materials and Methods {#sec2-jcm-09-02013}
========================

2.1. Study Participants {#sec2dot1-jcm-09-02013}
-----------------------

This study was approved by the Institutional Review Board of Seoul National University Hospital (IRB No. 0812-002-264). Informed consent was obtained from all individual participants and/or their parents. All methods were carried out in accordance with the Declaration of Helsinki. Two hundred ninety-one pediatric patients with an onset age of renal symptoms ≤20 years were recruited from 20 major pediatric nephrology centers in Korea. All patients had persistent proteinuria (spot urine protein/creatinine ratio \>0.2 mg/mg) or fully developed NS. Most patients showed resistance to conventional oral steroid therapy either at the initial presentation (initial steroid non-responders) or during follow-up (late steroid non-responders). Based on the KDIGO (Kidney Disease: Improving Global Outcomes) clinical practice guideline for management of glomerulonephritis \[[@B15-jcm-09-02013]\], an initial non-responder is defined as "failure to achieve complete remission after 8 weeks of corticosteroid therapy", and a late non-responder is defined as "persistent proteinuria during 4 or more weeks of corticosteroids following one or more remissions". Some patients did not receive steroid treatment because they showed congenital onset, advanced stage of chronic kidney disease (CKD), or mild to moderate degree of proteinuria only at the initial presentation. Medical records of the patients were reviewed retrospectively.

2.2. Strategy of Mutational Studies {#sec2dot2-jcm-09-02013}
-----------------------------------

In most patients, screening of a single or few candidate genes using Sanger sequencing was performed first; (1) *NPHS1*, *NPHS2*, *WT1*, and *LAMB2* for patients with congenital (disease onset within the first 3 months of life) or infantile (disease onset at age 4--12 months) NS \[[@B12-jcm-09-02013],[@B13-jcm-09-02013]\]; (2) *INF2*, *ACTN4*, and *TRPC6* for patients with a family history of autosomal dominant (AD) inheritance; (3) *NPHS2* and *NUP107* for patients with a family history of autosomal recessive (AR) inheritance; and (4) corresponding causative gene for patients with syndrome diseases. In patients suspected of mitochondrial cytopathy, especially MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes) syndrome, heteroplasmy of the 3243A \> G variation in *MT-TL1* was tested by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) using the ApaI restriction enzyme \[[@B16-jcm-09-02013]\]. Then, TES or WES were performed for the remaining patients and those patients with negative results in the initial screening tests.

2.3. Targeted Exome Sequencing (TES) and Variant Calling {#sec2dot3-jcm-09-02013}
--------------------------------------------------------

The gene panel for TES covered 57 genes known to be associated with SRNS or FSGS at that time ([Supplementary Table S1](#app1-jcm-09-02013){ref-type="app"}). Genomic DNA was extracted from whole blood using QIAamp DNA mini kits (Qiagen, Valencia, CA, USA). The quality or quantity of DNA was checked using a Nanodrop 8000 ultraviolet--visible (UV--Vis) spectrometer (Thermo Scientific, Waltham, MA, USA) and Qubit 2.0 Fluorometer (Life Technologies, Grand Island, NY, USA). Genomic DNA was sheared by a Covaris S220 (Covaris, Woburn, MA, USA). Targeted exome capture was performed using a SureSelect XT customized kit (Agilent Technologies, Santa Clara, CA, USA). Sequencing was performed on the HiSeq 2500 platform with paired-end 100-bp reads (Illumina, San Diego, CA, USA).

Sequenced reads were aligned to the human reference genome (hg19) using the Burrows--Wheeler alignment (BWA) tool with the maximal exact match (MEM) algorithm (version 0.7.5) \[[@B17-jcm-09-02013]\]. SAMtools (version 0.1.18) \[[@B18-jcm-09-02013]\], Picard Tools (version 1.93, <https://broadinstitute.github.io/picard/>, accessed on 31 January 2020) and GATK (version 3.1-3) \[[@B19-jcm-09-02013]\] were used for manipulating aligned sequenced data. Single nucleotide variants and InDels (insertions/deletions) were detected by UnifiedGenotyper in GATK. Various information, such as mutation nomenclature, dbSNP id, minor allele frequency of ExAC (the Exome Aggregation Consortium), and LJB23 databases, were annotated for each variant by ANNOVAR (Annotate Variation) \[[@B20-jcm-09-02013]\]. Several filtering steps were applied to obtain candidates from germline variants; (1) variants with very low VAF (\<5%), (2) variants with minor allele frequency (\>1%) in the 1000GP3, and (3) variants in genes not related to the disease. Interpretation of variants followed the American College of Medical Genetics and Genomics (ACMG) guidelines, and variants classified as pathogenic or likely pathogenic were considered to be disease-causing mutations after confirmation by Sanger sequencing \[[@B21-jcm-09-02013]\].

2.4. Whole-Exome Sequencing (WES) and Variant Calling {#sec2dot4-jcm-09-02013}
-----------------------------------------------------

The procedures used for the preparation of genomic DNA, whole-exome capture using an Agilent V5 array, sequencing using the Illumina HiSeq 2500 platform (Illumina, San Diego, CA, USA), read alignment, variant calling, variant filtering and de novo variant calling have been described previously \[[@B22-jcm-09-02013]\].

2.5. Statistical Analysis {#sec2dot5-jcm-09-02013}
-------------------------

To determine significant differences between groups with or without pathogenic variants, categorical variables were analyzed using the chi-square test or Fisher's exact test, and continuous variables were compared using the *t*-test or Mann--Whitney U test. All values are reported as the median (interquartile range, IQR). The statistical analysis was performed using SPSS version 24.0 (SPSS, Armonk, NY, USA).

3. Results {#sec3-jcm-09-02013}
==========

3.1. Phenotypes {#sec3dot1-jcm-09-02013}
---------------

The clinical features of the patients are summarized in [Table 1](#jcm-09-02013-t001){ref-type="table"}. A total of 291 unrelated pediatric patients (male:female = 162:129) with SRNS/FSGS were recruited for this study. The median onset age was 3.9 years (IQR 1.5--9.2 years), and the median duration of follow-up from the onset was 8.0 years (IQR 3.4--13.3 years). None of the patients were offspring of a consanguineous couple, and 48 (16.4%) patients had a family history of kidney disease.

Regarding age of onset, 35 (12.2%) patients showed congenital onset, and 25 (8.6%) patients showed infantile onset. One hundred seventy-seven (60.8%) patients presented with NS, 93 (32.0%) patients with proteinuria, and 19 (6.5%) patients with CKD or ESRD. Conventional steroid therapy was administered to 206 patients, and 191 (92.7%) patients showed steroid resistance. In 83 patients, steroid therapy was not performed because they presented with congenital onset (*n* = 32), advanced stage of CKD (*n* = 29), or a mild to moderate degree of proteinuria only (*n* = 22). Kidney biopsy was performed in 236 patients and FSGS revealed in 165 (69.9%) patients, minimal change disease in 31 (13.1%) patients, and other lesions in 40 (16.9%) patients. During follow-up, 113 (38.8%) patients had maintained a normal estimated glomerular filtration rate (eGFR), 29 (10.0%) patients progressed to CKD stages 2--4, and 144 (49.5%) patients progressed to ESRD. Kidney transplantation was performed in 100 patients, including 71 patients with FSGS, nine of whom had recurrence of SRNS/FSGS in the graft kidney.

3.2. Genotypes {#sec3dot2-jcm-09-02013}
--------------

The overall detection rate of disease-causing mutations was 43.6% (127 of 291 patients): 80 (27.5%) patients by Sanger sequencing, three (1.0%) patients with MELAS syndrome by PCR-RFLP of the *MT-TL1* gene, four (1.4%) patients by WES, and 40 (13.7%) patients by TES. Among 127 patients with disease-causing mutations, 59 (46.5%) patients had AD mutations, 58 (45.7%) patients had AR mutations, and 10 (7.9%) patients had X-linked or mitochondrial mutations.

*WT1* was the most common causative gene (23.6%, 30 patients), followed by *COQ6* (9.4%, 12 patients), *NPHS1* (8.7%, 11 patients), *NUP107* (7.1%, 9 patients), *COQ8B* (6.3%, 8 patients), *MYH9* (4.7%, 6 patients), and *INF2* (4.7%, 6 patients) ([Table 2](#jcm-09-02013-t002){ref-type="table"}). There were 14 patients with mutations in phenocopy genes, including *COL4A3--5* and *WDR19* ([Table 2](#jcm-09-02013-t002){ref-type="table"}). The genotypes and clinical features of patients with disease-causing mutations are summarized in [Supplementary Table S2](#app1-jcm-09-02013){ref-type="app"}. In addition, variants of unknown significance (VUS) were detected by TES in 23 additional patients ([Supplementary Table S3](#app1-jcm-09-02013){ref-type="app"}).

3.3. Genotype-Phenotype Correlations {#sec3dot3-jcm-09-02013}
------------------------------------

A comparison between patients with disease-causing mutations and patients without mutations is summarized in [Table 1](#jcm-09-02013-t001){ref-type="table"}. The mutation detection rate was 77.1% in patients with congenital onset, which was significantly higher than that in patients with older disease onset (38.7%, *p* \< 0.001). The rate was lower in patients presenting with NS than in patients presenting with proteinuria or CKD/ESRD (34.5% versus 57.1%, *p* \< 0.001). Patients who did not receive steroid treatment showed a higher mutation detection rate than steroid non-responders (63.9% versus 37.7%, *p* \< 0.001). None of the steroid responders and only one of 12 steroid late non-responders had mutations. Moreover, mutations were not detected in any of the patients with minimal change disease. Interestingly, the mutation detection rate showed a negative correlation with the current eGFR of the patients: 15.0% in patients with normal eGFR, 37.9% in patients with CKD stages 2--4, and 67.4% in patients with ESRD ([Table 1](#jcm-09-02013-t001){ref-type="table"} and [Figure 1](#jcm-09-02013-f001){ref-type="fig"}). The rate of progression to ESRD showed no significant difference between the mutation (+) and mutation (−) groups, and disease recurrence in the graft kidney was noted in the latter group only.

Comparison between patients with AD mutations and patients with AR mutations showed that most (11 of 12) patients with disease onset ≥13 years had AD mutations ([Supplementary Table S4](#app1-jcm-09-02013){ref-type="app"} and [Figure 2](#jcm-09-02013-f002){ref-type="fig"}). Other clinical parameters showed no significant difference between the two groups.

4. Discussion {#sec4-jcm-09-02013}
=============

In this work, of 291 Korean children with SRNS or FSGS, genetic mutations were identified in 127 patients (43.6%) in one of 26 causative genes. Thirty different novel mutations detected in 15 causative genes are described in [Supplemental Table S2](#app1-jcm-09-02013){ref-type="app"}. The mutation detection rate was higher than the 23.6--30.3% reported by previous large cohort studies from Western and Asian countries ([Table 3](#jcm-09-02013-t003){ref-type="table"}). Such differences cannot be explained clearly, but the size of the sample database, selection bias of the target patients, and differences in ethnicity may play some role.

One of the most striking differences in this study compared with studies from other countries was the low prevalence of *NPHS2* mutations---1.4% of total patients and 3.1% of patients with mutations. In 2015, two large international cohort studies, the PodoNet Registry study \[[@B3-jcm-09-02013]\] and the SRNS Study Group \[[@B4-jcm-09-02013]\], using a panel of genes covering 31 and 27 candidate genes, respectively, were published. In these studies, *NPHS2* was the most commonly mutated gene (49.8% and 33.7% of patients with mutations, respectively), and the sum of three major causative genes (*NPHS2*, *NPHS1*, and *WT1*) accounted for 81.9% and 74.8% of total mutations, respectively. In 2017, another study from the United Kingdom using WES with a focus on 53 genes was published \[[@B2-jcm-09-02013]\]. In this study, the proportion of mutations in *NPHS2* and the sum of three major causative genes (*NPHS2*, *NPHS1*, and *WT1*) were 24.5% and 61.3%, respectively. The difference between the studies published in 2015 and 2017 may be due, at least in part, to differences in the number of genes studied. An international study \[[@B23-jcm-09-02013]\] using WES showed a low prevalence of *NPHS2* and *WT1* mutations because many enrolled individuals were screened for mutations in *WT1* and *NPHS2* before performing WES, and those who screened positive were excluded. Moreover, a Japanese study \[[@B6-jcm-09-02013]\] showed that none of the 230 unrelated patients with proteinuria had *NPHS2* mutations, and a Chinese study \[[@B5-jcm-09-02013]\] showed that *NPHS2* mutations were detected in 4 (3.3%) of 120 children with SRNS or isolated proteinuria, which accounted for 11.8% of 33 patients with disease-causing mutations. The lower prevalence of *NPHS2* mutations in Asian countries, including Korea, may be due to the absence of common mutations, i.e., a founder effect \[[@B4-jcm-09-02013],[@B24-jcm-09-02013],[@B25-jcm-09-02013]\]. Another interesting finding in this study is the higher prevalence of mutations in *COQ6*, *COQ8B* and *NUP107*, which was consistent with our previous studies \[[@B26-jcm-09-02013],[@B27-jcm-09-02013],[@B28-jcm-09-02013]\]. An increased prevalence of *COQ8B* mutations was also found in a Chinese study \[[@B5-jcm-09-02013]\], while an increased prevalence of *NUP107* mutations was found in a Japanese study \[[@B6-jcm-09-02013]\].

In this study, the mutation detection rate was higher in patients with congenital onset than in patients with other onset age groups (77.1% versus 38.7%, *p* \< 0.001). Previous reports \[[@B4-jcm-09-02013],[@B12-jcm-09-02013],[@B13-jcm-09-02013]\] have shown that the mutation detection rate is inversely related to age at disease onset in patients with SRNS. In a European study \[[@B12-jcm-09-02013]\], the mutation detection rates of congenital and infantile NS were 84.8% and 44.1%, respectively (66.3% in the first year combined). Similarly, a previous study \[[@B13-jcm-09-02013]\] from our group reported that the mutation detection rates of congenital and infantile NS were 93.9% and 20.2%, respectively (56.7% overall). In addition, a large international cohort study by the SRNS Study Group \[[@B4-jcm-09-02013]\] reported the mutation detection rate by onset age as follows: onset in the first 3 months of life (69.4%), between 4 and 12 months old (49.7%), between 1 and 6 years old (25.3%), between 7 and 12 years old (17.8%), and between 13 and 18 years old (10.8%).

This study showed a higher mutation detection rate in patients who presented with proteinuria than in patients who presented with NS (57.0% versus 34.5%, *p* \< 0.001). Similarly, in a Japanese study \[[@B6-jcm-09-02013]\], the absence of edema was one of the risk factors for genetic mutations in pediatric patients with severe proteinuria. In this study, the mutation detection rate was higher in patients without steroid treatment than in patients with initial steroid non-responsiveness (63.9% versus 39.7%, *p* \< 0.001). Most patients who did not receive steroid treatment in the present study presented with congenital onset, advanced stage CKD, or proteinuria, and these findings may contribute to the higher mutation detection rate. SRNS with AD mutations, except for *WT1* mutations, typically presents later in life, in adolescence or adulthood \[[@B4-jcm-09-02013],[@B7-jcm-09-02013]\]. This study also showed that 10 of 11 patients with disease onset over 13 years of age had AD mutations. Disease recurrence in the graft kidney was noted in the mutation (-) group only. The recurrence rate after transplantation in the mutation (−) group (25.8%, 8 of 31 patients) was lower than that in a previous report from a Korean tertiary center (50.0%, 18 of 36 idiopathic FSGS patients) \[[@B29-jcm-09-02013]\].

Early genetic diagnosis can benefit patients with SRNS in many ways. First, patients do not have to waste their time and money on an accurate diagnosis, i.e., a 'diagnostic odyssey' \[[@B14-jcm-09-02013],[@B30-jcm-09-02013]\]. Second, genetic diagnosis is essential for family counseling. Third, detection of certain mutations allows prediction and further screening of renal and extrarenal comorbidities and helps to avoid possible future complications, e.g., risk of Wilms' tumor or gonadoblastoma in patients with *WT1* mutations \[[@B31-jcm-09-02013],[@B32-jcm-09-02013]\]. Fourth, patients can avoid invasive diagnostic procedures (e.g., a kidney biopsy) and ineffective, possibly harmful, drug therapy. Fifth, some rare mutations are potentially treatable with other therapeutic options, e.g., coenzyme Q10 supplementation for mutations involving the coenzyme Q10 biosynthesis pathway, such as *COQ2*, *COQ6*, *COQ8B* or *PDSS2* mutations \[[@B33-jcm-09-02013],[@B34-jcm-09-02013],[@B35-jcm-09-02013]\]. Finally, genetic diagnosis is important for preparing a kidney transplantation in terms of donor evaluation in family members with AD mutations as well as predicting the possibility of recurrence of FSGS in the graft kidney \[[@B3-jcm-09-02013],[@B36-jcm-09-02013]\].

Ideally, genetic testing is recommended for all children with SRNS due to the relatively high overall mutation detection rate. If it is practically unfeasible, patients at high risk of genetic mutations should be selected. Commonly applied indications for genetic testing are as follows: (1) early age of onset (congenital or infantile); (2) a family history of SRNS or consanguinity; (3) presence of typical extrarenal manifestation of syndromic diseases; (4) progression to CKD or ESRD, and (5) preoperative evaluation for kidney transplantation \[[@B7-jcm-09-02013],[@B8-jcm-09-02013],[@B9-jcm-09-02013],[@B10-jcm-09-02013],[@B11-jcm-09-02013]\].

Fourteen (11.0% of patients with disease-causing mutations) patients in this study had mutations in four phenocopying genes, including *COL4A3--5* and *WDR19*. Because these cases manifested proteinuria or SRNS as the only evident clinical sign at disease onset or even later, they were clinically diagnosed with and treated for SRNS. A phenocopy is defined as "a phenotypic trait or disease that resembles the trait expressed by a particular genotype, but in an individual who is not a carrier of that genotype" \[[@B37-jcm-09-02013]\]. In a recent study \[[@B23-jcm-09-02013]\] in 300 families with SRNS using WES, 74 families (25%) had mutations in one of the known SRNS genes, and 11 families (3.7%) had mutations in genes that cause a phenocopy of SRNS. Landini et al. \[[@B38-jcm-09-02013]\] studied 64 young patients diagnosed with SRNS, and the exome sequencing results were filtered in silico for 298 genes related to CKD, including but not limited to SRNS-related genes. They found disease-causing variants in podocytopathy genes typically associated with SRNS and FSGS in 19 patients (30%) as well as pathogenic mutations in phenocopy genes, including *COL4A3--5* (Alport syndrome), *CLCN5* (Dent disease), *PAX2* (renal-coloboma syndrome), and *GLA* (Fabry disease), in 18 patients. In addition, they found distinct extrarenal phenotypes typical of the genetic diagnoses in all patients and/or first-degree relatives by post hoc thorough 'reverse phenotyping'. These findings highlight that, even in the era of genomics, precise and thorough phenotyping by clinicians remains essential for an accurate genetic diagnosis, including selection of the appropriate genetic testing method and interpretation of results \[[@B14-jcm-09-02013],[@B39-jcm-09-02013]\].

5. Conclusions {#sec5-jcm-09-02013}
==============

In conclusion, the overall mutation detection rate in this cohort of Korean pediatric patients with SRNS was 43.6%. Mutations in *COQ6*, *NUP107*, and *COQ8B* were more frequently detected, and mutations in *NPHS2* were less commonly detected in this cohort compared to study cohorts from Western countries. The mutation detection rate was higher in patients with congenital onset, those who presented with proteinuria or CKD/ESRD, and those who did not receive steroid treatment. The worse the current renal function was, the higher the mutation detection rate. Genetic tests should be performed for pediatric patients with SRNS, especially for patients with younger onset age, presentation with proteinuria or progression to advanced CKD stages.
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###### 

Genotype-phenotype correlations in pediatric patients with steroid-resistant nephrotic syndrome or focal segmental glomerulosclerosis.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Phenotype                                            Mutation (+) Patients\   Mutation (−) Patients\   Total Patients\   Mutation Detection Rate   *p* Value
                                                       (*n* = 127)              (*n* = 164)              (*n* = 291)                                 
  ---------------------------------------------------- ------------------------ ------------------------ ----------------- ------------------------- -------------
  Age at onset                                                                                                                                       

   Congenital                                          27 (21.3%)               8 (4.9%)                 35 (12.0%)        77.1%                     \<0.001 ^b^

   Infantile                                           11 (8.7%)                14 (8.5%)                25 (8.6%)         44.0%                     

   1--6 years                                          40 (31.5%)               74 (45.1%)               114 (39.2%)       35.1%                     

   7--12 years                                         32 (25.2%)               46 (28.0%)               78 (26.8%)        41.0%                     

   ≥13 years                                           15 (11.8%)               21 (12.8%)               36 (12.4%)        41.7%                     

   Data unavailable                                    2 (1.6%)                 1 (0.6%)                 3 (1.0%)                                    

  Sex ratio ^a^ (Male:female)                          71:56                    91:73                    162:129                                     

  Family history (+)                                   24 (18.9%)               24 (14.6%)               48 (16.5%)        50.0%                     

  Mode of onset                                                                                                                                      

   Nephrotic syndrome                                  61 (48.0%)               116 (70.7%)              177 (60.8%)       34.5%                     \<0.001 ^c^

   Proteinuria                                         53 (41.7%)               40 (24.4%)               93 (32.0%)        57.0%                     

   CKD/ESRD                                            11 (8.7%)                8 (4.9%)                 19 (6.5%)         57.9%                     

   Data unavailable                                    2 (1.6%)                 0                        2 (0.7%)                                    

  Steroid responsiveness                                                                                                                             

   Responder                                           0                        15 (9.1%)                15 (5.2%)         0%                        

   Non-responder                                       72 (56.7%)               119 (72.6%)              191 (65.6%)       37.7%                     

    Initial non-responder                              71                       108                      179               39.7%                     

    Late non-responder                                 1                        11                       12                8.3%                      

   No treatment                                        53 (41.7%)               30 (18.3%)               83 (28.5%)        63.9%                     \<0.001 ^d^

   Data unavailable                                    2 (1.6%)                 0                        2 (0.7%)                                    

  Renal biopsy                                                                                                                                       

   FSGS                                                78 (61.4%)               87 (53.0%)               165 (56.7%)       47.3%                     

   Minimal change disease                              0                        31 (18.9%)               31 (10.7%)        0%                        

   Others                                              20 (15.7%)               20 (12.2%)               40 (13.7%)        50.0%                     

   Not done                                            27 (21.3%)               23 (14.0%)               50 (17.2%)        54.0%                     

   Data unavailable                                    2 (1.6%)                 3 (1.8%)                 5 (1.7%)                                    

  Renal function at the last FU                        \<0.001 ^e^                                                                                   

   Normal eGFR                                         17 (13.4%)               96 (58.5%)               113 (38.8%)       15.0%                     

   CKD stages 2--4                                     11 (8.7%)                18 (11.0%)               29 (10.0%)        37.9%                     

   ESRD                                                97 (76.4%)               47 (28.7%)               144 (49.5%)       67.4%                     

   Data unavailable                                    2 (1.6%)                 3 (1.8%)                 5 (1.7%)                                    

  Duration (years) from onset to ESRD (*n* = 144)      3.6 ± 4.3                5.0 ± 4.8                4.1 ± 4.5                                   0.091

  Recurrence after renal transplantation (*n* = 100)   0/64 (0%)                9/36 (25.0%)             9/100 (9.0%)                                \<0.0001
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Sex of patients with *WT1* mutations and sex reversal followed by their karyotypes; ^b^ Congenital onset group (27/35, 77.1%) versus other onset age groups (98/253, 38.7%); ^c^ Nephrotic syndrome group (61/177, 34.5%) versus other mode of onset groups (64/112, 57.1%); ^d^ No steroid treatment group (53/83, 63.9%) versus steroid non-responders (72/191, 37.7%); ^e^ Among three groups: normal eGFR, CKD stage 2--4, and ESRD groups.; FSGS, focal segmental glomerulosclerosis; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; ESRD, end-stage renal disease; FU, follow-up.

jcm-09-02013-t002_Table 2

###### 

Mutation screening results.

  -----------------------------------------------------------------------------------------------
  Gene                Mode of Inheritance   No. of Patients\   \% of Total Patients (*n* = 291)
                                            (%)                
  ------------------- --------------------- ------------------ ----------------------------------
  SRNS/FSGS gene                                               

  *WT1*               AD                    30 (23.6%)         10.3%

  *COQ6*              AR                    12 (9.4%)          4.1%

  *NPHS1*             AR                    11 (8.7%)          3.8%

  *NUP107*            AR                    9 (7.1%)           3.1%

  *COQ8B*             AR                    8 (6.3%)           2.7%

  *MYH9*              AD                    6 (4.7%)           2.1%

  *INF2*              AD                    6 (4.7%)           2.1%

  *PAX2*              AD                    5 (3.9%)           1.7%

  *NPHS2*             AR                    4 (3.1%)           1.4%

  *MAFB*              AD                    4 (3.1%)           1.4%

  *LAMB2*             AR                    3 (2.4%)           1.0%

  *SMARCAL1*          AR                    3 (2.4%)           1.0%

  *MT-TL1*            Mitochondrial         3 (2.4%)           1.0%

  *ACTN4*             AD                    1 (0.8%)           0.3%

  *LMX1B*             AD                    1 (0.8%)           0.3%

  *ANLN*              AD                    1 (0.8%)           0.3%

  *TRPC6*             AD                    1 (0.8%)           0.3%

  *TP53RK*            AR                    1 (0.8%)           0.3%

  *PODXL*             AR                    1 (0.8%)           0.3%

  *DGKE*              AR                    1 (0.8%)           0.3%

  *FOXP3*             X-linked              1 (0.8%)           0.3%

  *LCAT*              AR                    1 (0.8%)           0.3%

  Subtotal                                  113 (89.0%)        38.8%

  Phenocopying gene                                            

  *COL4A5*            X-linked              6 (4.7%)           2.1%

  *COL4A4*            AD/AR                 4 (3.1%)           1.4%

  *WDR19*             AR                    3 (2.4%)           1.0%

  *COL4A3*            AD                    1 (0.8%)           0.3%

  Subtotal                                  14 (11.0%)         4.8%

  Total                                     127 (100%)         43.6%
  -----------------------------------------------------------------------------------------------

AD, autosomal dominant; AR, autosomal recessive.
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###### 

Genetic studies in large cohorts of pediatric patients with steroid-resistant nephrotic syndrome.

                               Trautmann et al., 2015 \[[@B3-jcm-09-02013]\]   Sadowski et al., 2015 \[[@B4-jcm-09-02013]\]   Bierzynska et al., 2017 \[[@B2-jcm-09-02013]\]   Wang et al., 2017 \[[@B5-jcm-09-02013]\]   Warejko et al., 2018 \[[@B23-jcm-09-02013]\]   Nagano et al., 2020 \[[@B6-jcm-09-02013]\]   This Study
  ---------------------------- ----------------------------------------------- ---------------------------------------------- ------------------------------------------------ ------------------------------------------ ---------------------------------------------- -------------------------------------------- --------------------------
  Country                      International                                   International                                  United Kingdom                                   China                                      International                                  Japan                                        Korea
  Modality                     GP (31 genes)                                   GP (27 genes)                                  WES (53 genes)                                   GP (28 genes)                              WES                                            GP (60 genes)                                Sanger/GP (57 genes) ^c^
  Detection rate ^a^           277/1174 (23.6%)                                526/1783 (29.5%)                               49/187 (26.2%)                                   34/120 (28.3%)                             85/300 (28.3%)                                 69/230 (30.0%)                               127/291 (43.6%)
  Commonly mutated genes ^b^   *NPHS2* 138 (49.8%)                             *NPHS2* 177 (33.7%)                            *NPHS1* 14 (28.6%)                               *COQ8B* 8 (23.5%)                          *NPHS1* 13 (15.3%)                             *WT1* 17 (24.6%)                             *WT1* 30 (23.6%)
  *WT1* 48 (17.3%)             *NPHS1* 131 (24.9%)                             *NPHS2* 12 (24.5%)                             *NPHS1* 7 (20.6%)                                *PLCE1* 11 (12.9%)                         *NPHS1* 8 (11.6%)                              *COQ6* 12 (9.4%)                             
  *NPHS1* 41 (14.8%)           *WT1* 85 (16.2%)                                *WT1* 4 (8.2%)                                 *WT1* 7 (20.6%)                                  *NPHS2* 8 (9.4%)                           *INF2* 8 (11.6%)                               *NPHS1* 11 (8.8%)                            
  *SMARCAL1* 12 (4.3%)         *PLCE1* 37 (7.0%)                               *NUP107* 4 (8.2%)                              *NPHS2* 4 (11.8%)                                *SMARCAL1* 8 (9.4%)                        *TRPC6* 7 (10.1%)                              *NUP107* 9 (7.1%)                            
  *PLCE1* 10 (3.6%)            *LAMB2* 20 (3.8%)                               *TRPC6* 3 (6.1%)                               *LMX1B* 2 (5.9%)                                 *LAMB2* 6 (7.1%)                           *LAMB2* 6 (8.7%)                               *COQ8B* 8 (6.3%)                             

^a^ Overall detection rate of mutations; ^b^ The parentheses denote the percentage of total patients with mutations. ^c^ WES (*n* = 4) and polymerase chain reaction-restriction fragment length polymorphism (*n* = 3) as well; GP, gene panel; WES, whole exome sequencing.
